Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Acute myeloid leukemia (AML) is a fatal bone marrow cancer with evolving treatment landscapes.
• Recent years have seen dramatic changes in AML diagnosis, risk assessment, monitoring, and therapy due to enhanced understanding and technology.

Purpose of the Study:

• To summarize the current state of AML management, including diagnosis, risk stratification, and therapeutic approaches.
• To highlight the impact of new biological insights and technological advancements on AML care.

Main Methods:

• Diagnosis relies on identifying immature leukemia cells in blood or bone marrow.
• Risk classification integrates cytogenetic and molecular findings, with prognostic factors varying by treatment approach.
• Measurable residual disease (MRD) quantification is increasingly used for response assessment and monitoring.

Main Results:

• At least 12 new therapies have been approved for AML.
• Optimal integration of novel agents into treatment algorithms is under active debate.
• Therapeutic strategies increasingly incorporate patient goals, comorbidities, and disease characteristics.

Conclusions:

• The management of AML has been significantly impacted by recent advancements.
• Personalized risk assessment and dynamic MRD monitoring are key components of modern AML therapy.
• Integrating new agents and patient-centered factors is essential for optimizing AML treatment strategies.